An update on biofilms in acute and chronic wounds: Incidence, clinical evidence, diagnosis, prevention, and treatment
Journal of Internal Medicine · 2026-10 · 300 (4) · 420-439
DOI: 10.1111/joim.70138 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Internal Medicine, online erschienen am 07.08.2026. Verfasst von Steven L Percival und 5 weiteren Autor:innen. Beteiligte Einrichtung: 5D Health Protection Group Ltd, Liverpool, UK. Hauptthemen laut MEDLINE: Biofilms, Wound Infection, Wounds and Injuries. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Wundversorgung
Abstract (Originalsprache)
Pathogenic biofilms are a critical barrier to wound healing, driving infection persistence, delayed tissue repair, and antimicrobial resistance (AMR) and tolerance. This recognition has driven a paradigm shift from a traditional planktonic model of infection to a biofilm‐mediated framework, where structured microbial communities are encased within a protective extracellular polymeric substance (EPS) matrix. These communities are highly prevalent in chronic wounds, with reported detection rates of 60%–100% across diabetic foot ulcers, venous leg ulcers, and pressure injuries. The establishment of biofilms fundamentally alters host–microbe interactions, promotes antimicrobial tolerance, and triggers therapeutic failure, prolonged inflammation, and wound chronicity. Despite their clinical relevance, management strategies remain limited. Crucially, a lack of rapid point‐of‐care diagnostics and standardized clinical endpoints hampers timely intervention. Conventional culture based methods frequently fail to detect sessile microbial populations, necessitating advanced techniques such as next‐generation sequencing or confocal microscopy, which are largely unavailable in routine practice. A detailed understanding of the molecular and cellular mechanisms underpinning biofilm persistence is essential to translate knowledge into targeted clinical interventions. Effective management requires a biofilm centric, multimodal strategy that prioritizes regular mechanical debridement to disrupt the EPS matrix, supported by proactive exudate control and appropriate topical therapies. Looking forward, advances in diagnostic technologies, artificial intelligence (AI)‐assisted analysis, and matrix disrupting or permeating agents offer significant potential. Furthermore, emerging biological therapies, including bacteriophages, promise to help transform wound management, reduce the burden of AMR, and potentially improve patient outcomes globally.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- 5D Health Protection Group Ltd, Liverpool, UK.
- Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.
- Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.
ORCID-Profile: Steven L Percival, Marcus J Swann, Kristian Daly, Dieter O Mayer, Prashini Moodley, Rui Chen
Zitieren
APA
Percival, S. L., Swann, M. J., Daly, K., Mayer, D. O., Moodley, P., & Chen, R. (2026). An update on biofilms in acute and chronic wounds: Incidence, clinical evidence, diagnosis, prevention, and treatment. Journal of Internal Medicine, 300(4), 420-439. https://doi.org/10.1111/joim.70138
Vancouver
Percival SL, Swann MJ, Daly K, Mayer DO, Moodley P, Chen R. An update on biofilms in acute and chronic wounds: Incidence, clinical evidence, diagnosis, prevention, and treatment. Journal of Internal Medicine. 2026;300(4):420-439. doi:10.1111/joim.70138
BibTeX
@article{Percival2026,
author = {Percival, Steven L and Swann, Marcus J and Daly, Kristian and Mayer, Dieter O and Moodley, Prashini and Chen, Rui},
title = {An update on biofilms in acute and chronic wounds: Incidence, clinical evidence, diagnosis, prevention, and treatment},
journal = {Journal of Internal Medicine},
year = {2026},
volume = {300},
number = {4},
pages = {420--439},
doi = {10.1111/joim.70138}
}
EUVIMED